Lexeo Therapeutics

Company snapshot

Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy researc

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Lexeo Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Lexeo Therapeutics.

1. Jun 8, 2026 Clinical update

   Low dose LX2006 — Phase 2

2. Jun 5, 2026 Clinical update

   LX2020 — Phase 2

3. Jun 5, 2026 Clinical update

   LX1001 — Phase 1

View all clinical trial activity →

• What is Lexeo Therapeutics?

  Lexeo Therapeutics is a biotech organization headquartered in New York, USA. It trades on NYSE under ticker LXEO. Primary therapeutic focus areas include Alzheimer Disease, Friedreich Ataxia, Arrhythmogenic Cardiomyopathy. NovaPharmaNews links 3 clinical program(s), 0 drug profil

• Is Lexeo Therapeutics publicly traded?

  Yes. Lexeo Therapeutics is listed with ticker LXEO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Lexeo Therapeutics develop or market?

  We link 4 drug profile(s) where Lexeo Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/lexeo-therapeutics#company-drugs.

• What are the latest developments for Lexeo Therapeutics?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Lexeo Therapeutics focus on?

  Lexeo Therapeutics focuses on Alzheimer Disease, Friedreich Ataxia, Arrhythmogenic Cardiomyopathy based on our analysis of their pipeline programs and drug development activities.